


# unleashing the untapped power of the immune system


atherosclerosis causes 4 of 10 deaths, with drug treatment limited to incremental advances in lipoprotein management  
our mission: reverse the disease, radically reduce its trillion-dollar burden, and save countless lives




- targeting oxidized cholesterol, a known driver of atherosclerosis with no current treatment options
- addressing the root cause of atherosclerotic inflammation, rather than downstream signaling
- a target with no biological function, which can be removed systemically without any negative effects
- efficient clinical development without the time and intricacies of a complex biologic approach
- enormous cross-disease and healthspan potential; primary CAD lead with pipeline development for neurodegenerative diseases, liver failure, and heart failure

\*combined adverse events outcomes over time (MI, heart failure, hospitalization, death, etc.) according to 7KC quartile (Song et al., 2017)

## undoing atherosclerosis:



introducing UDP-003, a custom-engineered small molecule with strong intellectual property protection and an excellent safety profile:



### world class advisors

- Prof. Prediman K. Shah, Founder and Director of the Oppenheimer Atherosclerosis Center, Cedars-Sinai Hospital
- Prof. Michael Farkouh, Associate Dean for Research and Clinical Trials, Cedars-Sinai Hospital
- Prof. Stephen Nicholls, Director of the Victorian Heart Institute, Monash University

... and, launching in 2025, the state-of-the-art in AI-based generative cyclodextrin development

### clinic ready

- one of the first UK Innovation Passport recipients
- completed successful FDA pre-IND and UK SAM
- cGMP manufacture in fill/finish stage
- in contract for phase 1, preclinical completes Q4

### efficient clinical path with early efficacy data

- safety data complete in early 2025
- phase 2 with plaque reduction endpoint 2027

### powerful team

- Mike Kope, Corp. Affairs CEO, 30+ years in biopharma with product launches and corporate exits
- Matthew O'Connor, Sci. Affairs CEO, 20+ years as a leader in the field of rejuvenation biotech